Cargando…

CAR-T cell therapy: a potential new strategy against prostate cancer

Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its low mutational burden. The recent development of chimeric antigen receptor (CAR)-T cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schepisi, Giuseppe, Cursano, Maria Concetta, Casadei, Chiara, Menna, Cecilia, Altavilla, Amelia, Lolli, Cristian, Cerchione, Claudio, Paganelli, Giovanni, Santini, Daniele, Tonini, Giuseppe, Martinelli, Giovanni, De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794851/ https://www.ncbi.nlm.nih.gov/pubmed/31619289 http://dx.doi.org/10.1186/s40425-019-0741-7

Ejemplares similares

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
por: Cursano, Maria Concetta, et al.
Publicado: (2020)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
por: Casadei, Chiara, et al.
Publicado: (2019)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support
por: De Padova, Silvia, et al.
Publicado: (2019)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
por: Cursano, M. C., et al.
Publicado: (2022)

Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer
por: Bleve, Sara, et al.
Publicado: (2022)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

Psychosocial Issues in Long-Term Survivors of Testicular Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma
por: Lolli, Cristian, et al.
Publicado: (2018)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

Vitamin D status among long-term survivors of testicular cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2016)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
por: Canale, Filippo A., et al.
Publicado: (2023)

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
por: Gianni, Caterina, et al.
Publicado: (2022)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
por: De Giorgi, Ugo, et al.
Publicado: (2020)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

Brief letter of a doctor to his psychologist in the COVID-19 outbreak era
por: Santini, Daniele, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6qmhva9na1qpavo3cfcnsn67o3